LACDPH Health Update:
UPDATE ON EBOLA VIRUS DISEASE (EVD) IN WEST AFRICA

This message is intended for primary care, urgent care, emergency medicine, internal medicine, travel medicine and infectious disease providers. Please distribute as appropriate.

Key communication

- There currently are no recognized cases of EVD in the U.S. other than a healthcare worker who became sick in Liberia and was transported to a hospital in Nebraska for care.
- EVD epidemic areas in West Africa have expanded to include the countries of Guinea, Liberia, Sierra Leone, and the cities Lagos and Port Harcourt, Nigeria, and Dakar, Senegal.
- A separate EVD outbreak also is ongoing in the Democratic Republic of Congo (DRC).
- Healthcare providers should obtain a travel history for all persons presenting with fever; persons who had been in the outbreak area during the prior 21 days should be isolated with standard, contact and droplet precautions while further evaluation is done.
- All persons with a positive travel history and who have fever should be reported immediately to the Acute Communicable Disease Control Program (ACDC), LAC DPH at 213-240-7941 (nights/weekends: 213-974-1234); a physician will provide consultation and guidance on management and whether Ebola testing is needed.
- The LA County Public Health Laboratory (PHL) has the capability to test for Ebola using the CDC authorized EUA Ebola real-time PCR assay. Testing will be done only after consultation with an ACDC physician. PHL staff will assist in packaging and pick-up specimens from hospitals. Do not send specimens by courier.

Situation

The EVD epidemic in West Africa has continued to spread. Recent cases in Port Harcourt, Nigeria, and Dakar, Senegal, have led to an expanded definition of the outbreak area to include these cities in addition to Guinea, Liberia, Sierra Leone, and Lagos, Nigeria. Over 3,600 confirmed and suspected cases and 1,800 deaths have occurred. A separate Ebola outbreak also is ongoing in a remote area of the Democratic Republic of Congo.

Over 70 suspect cases have been evaluated to date at U.S. hospitals. Fewer than 10 were tested for Ebola and no confirmed cases have been identified. In LA County, 4 patients have been assessed. None had identified exposure in W. Africa to a person with Ebola, all had alternative diagnoses made, and none required Ebola testing.
While the likelihood of imported EVD cases in the U.S. still is considered low, knowing the right approach to evaluation, reporting, and management of persons with potential EVD is critical to reduce the risk of transmission and to provide optimal care.

**Actions requested of providers**

- Ensure that persons with fever who present for acute care are asked about recent travel to the Ebola outbreak area. As the outbreak will likely continue to spread, periodically check for updates on the CDC Website at: [http://www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html](http://www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html).
- Review the Assessment and Management of Persons with Potential EVD using the attached algorithm. This algorithm and associated tables 1-5 provide step-by-step guidance regarding the assessment, work-up, management, and reporting of suspect EVD cases in LAC. Changes in the algorithm since the previous HAN (August 14, 2014) include:
  - Request that all persons with travel to the outbreak area during the prior 21 days and with fever (T ≥101.5 F or 38.6 C) be immediately reported to LAC DPH, ACDC
  - Updated definition of the outbreak area (Table 1)
  - Clarification of the criteria for the Low-Risk and No Identified Risk categories (Table 2)

**Submitting specimens to the LAC PHL for testing**

Testing will be done only after consultation and approval by an ACDC physician. Submit two whole blood specimens in purple, yellow or blue top vacutainers. Specimens approved for Ebola PCR testing at the public health laboratory should be accompanied by the following forms:

1) Public Health Laboratory test requisition: [http://www.publichealth.lacounty.gov/lab/docs/H-3021%20Test%20Request%20Form.pdf](http://www.publichealth.lacounty.gov/lab/docs/H-3021%20Test%20Request%20Form.pdf)

2) CDC Form 50.34: [http://www.cdc.gov/laboratory/specimen-submission/form.html](http://www.cdc.gov/laboratory/specimen-submission/form.html)


**Reporting potential EVD cases in LAC:**

- Weekdays 8:00 am-5:00 pm call (213) 240-7941
- Non-business hours (before 8:00 am, after 5:00 pm, or weekends) call (213) 974-1234

*Reporting suspect cases in the cities of Long Beach or Pasadena*, contact the local health department at the following numbers 24 hours/day:

- Long Beach HD: (562) 435-6711
- Pasadena HD: (626) 744-6043

**Additional Resources**
• LAC DPH webpage: http://www.lapublichealth.com/acd/diseases/Ebola.htm

• Centers for Disease Control and Prevention (CDC) webpages:

This Health Update was sent by Dr. Laurene Mascola, Chief, Acute Communicable Disease Control Program, Los Angeles County Department of Public Health.

Please visit our LAHAN webpage to view this and other communications: http://publichealth.lacounty.gov/lahan
Evaluation of Persons for Potential Ebola Exposure and Illness
LA County (LAC) Acute Communicable Disease Control (ACDC) Program

This algorithm provides guidance for clinicians evaluating a patient for suspect Ebola virus disease (EVD). Evaluation for suspect EVD should be limited to persons who have traveled or worked in the epidemic area during the previous 21 days (see Table 1). Persons who have not been in the epidemic area during this period are not at risk for EVD and should be evaluated for other causes of illness. Updated information will be provided on the LAC Department of Public Health (DPH) website (http://www.lapublichealth.com/acd/diseases/Ebola.htm) and on the CDC website (http://www.cdc.gov/vhf/ebola/hcp/index.html) should the epidemic area change.

Persons with a positive travel history should be evaluated for fever and other symptoms, and for exposure to EVD patients, as described in the algorithm, below. During evaluation, keep patients in a private room with the door closed; limit entry and maintain a log of people who enter the room; use standard, contact and droplet precautions; and perform only essential diagnostic and laboratory testing. Physicians at ACDC are available for consultation regarding assessment of patients. All persons with a positive travel history and fever should be reported immediately to ACDC (weekdays: 213-240-7941; nights/weekends: 213-974-1234). Persons with a positive travel history, no identified risk factors and no symptoms should be reassured and told to self-monitor for fever or other symptoms and return for care as needed. Reporting is not required for those with no identified risks and who are asymptomatic.

Laboratory testing for suspect EVD using PCR is available at the LAC Public Health Laboratory (PHL). Consultation with ACDC is required for testing at LAC PHL or at CDC; assistance in specimen handling will be provided by the LAC PHL.

Algorithm for assessment and management of persons with suspect EVD

*Refer to designated table (T) and column or row as indicated
Tables 1-5: Assessment and management of persons with potential EVD

Table 1. EBOLA RISK AREAS

| Current outbreak (as of 9/5/14): Guinea; Liberia; Sierra Leone; Lagos and Port Harcourt, Nigeria; Dakar, Senegal. A second outbreak (different virus strain) also is ongoing in the Democratic Republic of Congo |

Table 2. EXPOSURE RISK

<table>
<thead>
<tr>
<th>1 - High risk</th>
<th>2 - Low risk</th>
<th>3 - No identified risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Percutaneous (e.g., needle stick) or mucous membrane exposure to body fluids of EVD patient</td>
<td>• Household member or other close contact (within 3 feet) with an EVD patient</td>
<td>• Having been in a country in which an EVD outbreak occurred within the past 21 days and having had no high or low risk exposures</td>
</tr>
<tr>
<td>• Direct care of an EVD patient or exposure to body fluids without appropriate personal protective equipment (PPE)</td>
<td>• Other close contact with an EVD patient in a healthcare facility or community setting</td>
<td></td>
</tr>
<tr>
<td>• Laboratory worker processing body fluids of confirmed EVD patients without appropriate PPE or standard biosafety precautions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Participation in funeral rites which include direct exposure to human remains in the geographic area where outbreak is occurring without appropriate PPE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. SYMPTOMS AND SIGNS

| 1 - Fever: T > 38.6 C / 101.5 F or subjective history of fever |
| 2 - Other symptoms: Headache, joint and muscle aches, abdominal pain, weakness, diarrhea, vomiting, stomach pain, lack of appetite, rash, red eyes, hiccups, cough, chest pain, difficulty breathing, difficulty swallowing, bleeding internally or externally |
| 3 - Hemorrhage and multi-organ failure: Bleeding from GI tract or other sites, shock, DIC, renal failure, hemodynamic instability, or other symptoms/signs of severe illness |

Table 4. ISOLATION AND MOVEMENT RESTRICTIONS

<table>
<thead>
<tr>
<th>1 - Isolation:</th>
<th>2 - Conditional release: Monitoring by public health authority; twice-daily self-monitoring for fever; notify public health authority if fever or other symptoms develop</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Single patient room with the door closed; limit entry of personnel to room</td>
<td></td>
</tr>
<tr>
<td>• Standard, contact and droplet precautions</td>
<td></td>
</tr>
<tr>
<td>• Limit phlebotomy and only perform essential diagnostic and clinical laboratory tests.</td>
<td></td>
</tr>
<tr>
<td>• PPE – Gloves, gown, eye protection (goggles or face shield); facemask; additional PPE if copious blood or other fluid in the environment would include double gloving, disposable shoe covering, leg covering. Discard PPE on leaving room taking care to avoid contamination when removing; hand hygiene immediately after removing PPE</td>
<td></td>
</tr>
<tr>
<td>• Aerosol generating procedures – Limit procedures as possible. If procedures required, conduct in a private room and ideally an Airborne Infection Isolation Room (AIIR). Personnel should use respiratory protection that is at least as protective as a NIOSH certified fit-tested N95 filtering facepiece respirator or higher (e.g., powered air purifying respiratory or elastomeric respirator)</td>
<td></td>
</tr>
<tr>
<td>3 - Controlled movement: Notification of public health authority; no travel by commercial conveyances (airplane, ship, train, bus, taxi); timely access to appropriate medical care if symptoms develop</td>
<td></td>
</tr>
<tr>
<td>4 - Self-monitor: Check temperature and monitor for other symptoms</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. RECOMMENDATIONS FOR SPECIMEN COLLECTION, HANDLING AND TRANSPORTATION

Contact the LAC DPH Laboratory Bioterrorism Response Unit (562-658-1360) for consultation on laboratory testing for Ebola. Procedures for the collection, handling , transportation, and testing of specimens for EVD issued by CDC is posted at: [http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html](http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html).